ADMA Biologics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock RAMSEY, NJ and

ADMA Biologics Announces Closing of Full

Exercise of Underwriters' Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

RAMSEY, NJ and BOCA RATON, FL, February 24, 2020 -- ADMA

Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,

marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection

and others at risk for certain infectious diseases, today announced the closing of the issuance of an additional 3,525,000 shares

of its common stock at a public offering price of $3.50 per share. The shares were issued pursuant to the full exercise of the

underwriters' overallotment option in connection with ADMA's previously announced underwritten public offering of 23,500,000

shares of its common stock. The gross proceeds from the exercise of the overallotment option were approximately $12.3 million,

bringing the total gross proceeds to ADMA from the offering to approximately $94.6 million, before deducting underwriting discounts

and commissions and other estimated offering expenses.

ADMA intends to use the net proceeds from this offering (i)

for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV; (ii) to support the ongoing commercial sales

of BIVIGAM and ASCENIV; (iii) to expand the manufacturing capacity of its Boca Facility, including supply chain functions, and

enhance the robustness of its supply chain oversight; (iv) to expand its plasma collection facility network; (v) for research and

development and business development opportunities; and (vi) for general corporate purposes and other capital expenditures.

Morgan Stanley and Jefferies LLC acted as joint book-running

managers for the offering. Oppenheimer & Co. Inc. acted as co-manager for the offering.

The offering was made only by means of a prospectus supplement

and accompanying prospectus forming part of a "shelf" registration statement on Form S-3 (File No. 333-234107) previously

filed with the Securities and Exchange Commission ("SEC") on October 4, 2019, and declared effective by the SEC on

October 15, 2019. The final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC

and is available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying

prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York,

NY 10014, Attention: Prospectus Department, or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison

Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by e-mail at: Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or

the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state

or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities

laws of any such state or jurisdiction.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical

company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient

patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three

United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and

the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral

immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI; and

NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA's mission

is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for

the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer

from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents:

9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we,"

"our" or the "Company"). Forward-looking statements include, without limitation, any statement that may

predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as "estimate,"

"project," "intend," "forecast," "target," "anticipate," "plan,"

"planning," "expect," "believe," "will," "is likely," "will likely,"

"should," "could," "would," "may," or, in each case, their negative, or words or

expressions of similar meaning. These forward-looking statements include statements about the offering and ADMA's intended

use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document

due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance

that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by

applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions

to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors

that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or

implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions

and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our

filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any

Executive Vice President and Chief Financial Officer | 201-478-5552

|www.admabiologics.com

INVESTOR RELATIONS CONTACT:

Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com